News & Events

Vivoryon Therapeutics attends CTAD 2019

HALLE (SAALE), Germany, 27 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today that management of Vivoryon Therapeutics will attend the CTAD […]

Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019

HALLE (SAALE), Germany, 21 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its third quarter financial results and a business update for the period […]

Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019

HALLE (SAALE), Germany, 4 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), announced today that the company is scheduled to attend and present at upcoming conferences […]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.

Vivoryon Therapeutics AG Successfully Completes a EUR 43 Million Capital Raise                            HALLE (SAALE), Germany, 24 October 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN: DE0007921835, […]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.

Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments                            HALLE (SAALE), Germany, 08 October […]

Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update

Conference call and webcast in English at 3:00 pm CEST / 09:00 am EST Successful private placement of EUR 8.2 million Strategic collaboration with MorphoSys announced in July […]

Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019

HALLE (SAALE), Germany, 22 August 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its Half Year Results for 2019 on Thursday, August 29, 2019. The […]

MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology

HALLE (SAALE) and PLANEGG/MUNICH Germany, 8 July 2019: Vivoryon Therapeutics AG (Euronext Amsterdam: VVY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: […]

Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio

HALLE (SAALE), Germany, 27 June 2019 – Vivoryon Therapeutics AG, (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835) announced today that they have […]